+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

  • PDF Icon


  • 24 Pages
  • August 2018
  • Region: Global
  • GlobalData
  • ID: 4655556
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis


This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.

The briefing includes analysis of KOL opinion on the following topic areas:
  • Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)

  • Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)

  • Views on dose response for upadacitinib

Key Highlights:
  • Majority of KOLs had a positive opinion of upadacitinib’s efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial

  • Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial

  • KOLs appeared unsure of upadacitinib’s comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)

  • In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

  • Interviews performed in Q2 2018

  • KOL data is analyzed to produce: Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts.

Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

Executive Summary
Research Panel Composition
Results & Implications

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie
  • Pfizer
  • Lilly
  • Gilead
  • Galapagos